← All trials
NCT06631287
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 11, 2024
- Primary completion
- Nov 1, 2026
- Completion date
- Jul 1, 2027
- First posted
- Oct 8, 2024
- Last posted
- Oct 23, 2024
- Enrollment
- 550
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Vanderbilt UniversityLead sponsor
- Vanderbilt UniversityOfficial
- National Institutes of Health (NIH)Collaborator
- Vanderbilt UniversitySponsor investigator
- National Institute on Aging (NIA)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.